38 research outputs found
Ketorolac vs. morfina nel trattamento del dolore acuto in pazienti traumatizzati: unâanalisi di minimizzazione dei costi
Aim of this study is to develop an economic valuation comparing ketorolac vs. morphine for the treatment of sharp pain caused by heavy limb injury, in traumatology ward and in first aid ward. As cost minimization analysis, this economic valuation has been based on clinical results of Rainer et al. (2000). Ketorolac and morphine have the same efficacy in calming the pain; the greatest difference in the clinical outcomes is about the morphine side effects (nausea, vomiting and phlebitis). Assuming the hospital point of view with a differential costs perspective, the ketorolac patients showed two consequences than could generate lower resources consumption: less side effects and the reduction of time permanence in first aid ward. Considering the drug cost, the administration cost and the side effects treatment costs, the expenditure for every single morphine patient is L. 23.385, vs L. 4.875 for a ketorolac patient, with a difference of L. 18.510
Lo studio FAST: FAringotonsillite STreptococcica in etĂ pediatrica Impatto farmacoeconomico delle Linee Guida dell'American Academy of Pediatrics sulla pratica clinica di 600 pediatri italiani
The American Academy of Pediatrics (AAP) has recently published its new guidelines for the treatment of pediatric tonsillopharyngitis; a diagnostic test for the detection of streptococci is recommended, followed by a treatment with penicillins (10 days) or cephalosporins (5 days) in case of positivity, and by no treatment otherwise. The success of a guideline, in general, depends on its diffusion in practice and on its adaptability to different local settings. The aim of the present study (FAST) was the evaluation of the clinical and economical impact of the application of the AAP guidelines in the Italian reality. The study was conducted with the cooperation of 600 pediatricians, uniformly distributed on the Italian territory, and involved 3072 patients. The pediatricians were left free to decide whether to follow the guidelines or not. The results of the analysis indicate that only some 20% of the pediatricians adhered to the suggested protocol; the total cost (calculated in the perspective of the National Health System, with a time horizon of about 3 months) per patient, nonetheless, resulted inferior in the group treated according to the proposed protocol (50,45 âą vs. 53,30 âą). Furthermore, a lower incidence of complications occurred in these patients. Among the "off-protocol" behaviors, two showed particularly evident misuse of health resources: inappropriate treatment after test positivity (59,15 âą/patient), and treatment after test negativity (14% of the total population). Another interesting, although not surprising, result of this study was the evidence that penicillins are as effective as cephalosporins in the short-term, but significantly inferior in terms of complications, positivity for streptococci at the control test, and complications detected at follow-up
Ketorolac vs. morfina nel trattamento del dolore acuto in pazienti traumatizzati: un'analisi di minimizzazione dei costi
Aim of this study is to develop an economic valuation comparing ketorolac vs. morphine for the treatment of sharp pain caused by heavy limb injury, in traumatology ward and in first aid ward. As cost minimization analysis, this economic valuation has been based on clinical results of Rainer et al. (2000). Ketorolac and morphine have the same efficacy in calming the pain; the greatest difference in the clinical outcomes is about the morphine side effects (nausea, vomiting and phlebitis). Assuming the hospital point of view with a differential costs perspective, the ketorolac patients showed two consequences than could generate lower resources consumption: less side effects and the reduction of time permanence in first aid ward. Considering the drug cost, the administration cost and the side effects treatment costs, the expenditure for every single morphine patient is L. 23.385, vs L. 4.875 for a ketorolac patient, with a difference of L. 18.510
Lo studio FAST: FAringotonsillite STreptococcica in etĂ pediatrica Impatto farmacoeconomico delle Linee Guida dellâAmerican Academy of Pediatrics sulla pratica clinica di 600 pediatri italiani
The American Academy of Pediatrics (AAP) has recently published its new guidelines for the treatment of pediatric tonsillopharyngitis; a diagnostic test for the detection of streptococci is recommended, followed by a treatment with penicillins (10 days) or cephalosporins (5 days) in case of positivity, and by no treatment otherwise. The success of a guideline, in general, depends on its diffusion in practice and on its adaptability to different local settings. The aim of the present study (FAST) was the evaluation of the clinical and economical impact of the application of the AAP guidelines in the Italian reality. The study was conducted with the cooperation of 600 pediatricians, uniformly distributed on the Italian territory, and involved 3072 patients. The pediatricians were left free to decide whether to follow the guidelines or not. The results of the analysis indicate that only some 20% of the pediatricians adhered to the suggested protocol; the total cost (calculated in the perspective of the National Health System, with a time horizon of about 3 months) per patient, nonetheless, resulted inferior in the group treated according to the proposed protocol (50,45 âą vs. 53,30 âą). Furthermore, a lower incidence of complications occurred in these patients. Among the âoff-protocolâ behaviors, two showed particularly evident misuse of health resources: inappropriate treatment after test positivity (59,15 âą/patient), and treatment after test negativity (14% of the total population). Another interesting, although not surprising, result of this study was the evidence that penicillins are as effective as cephalosporins in the short-term, but significantly inferior in terms of complications, positivity for streptococci at the control test, and complications detected at follow-up
Burden of Crohn's disease: economics and quality of life aspects in Italy.
BACKGROUND: This was a prospective observational study designed to evaluate direct and indirect costs and quality of life for patients with Crohn's disease in Italy from the perspectives of the National Health System and of society.
METHODS: A total of 162 male and female subjects aged 18-70 years with Crohn's disease in the active phase and a Crohn's Disease Activity Index score â„150 were included in the study. Subjects were recruited from 25 Italian centers on a consecutive basis. The study consisted of four visits undertaken every 6 months with a follow-up period of 18 months. The study started on September 1, 2006 and was completed on April 12, 2010. Multivariate analyses were carried out on demographic characteristics, treatment costs based on the prescribed daily dose, resource use and other cost parameters, and changes in quality of life using the EQ5D questionnaire.
RESULTS: Cost of illness per subject with Crohn's disease in Italy was estimated to be âŹ15,521 per year, with direct costs representing 76% of total costs. Nonhealth care costs and loss of productivity accounted for 24% of total costs. Societal costs during the first months of enrolment were higher compared with costs in the final months of the study. Quality of life measured by the EQ-5D was 0.558 initially and then increased to 0.739, with a mean value of 0.677 during the enrolment period. The cost of illness was not correlated with age or gender.
CONCLUSION: The cost of illness was correlated with quality of life; Crohn's disease had a negative impact on subjects' quality of life, and higher costs corresponded to a lower quality of life as measured with the EQ5D. Drug treatment may improve quality of life and reduce hospitalization costs. Our results appear to be in line with the results of other international cost-of-illness studie
Electric field effects on proteins Novel perspectives on food and potential health implications
Electric fields (EF) technologies have been establishing a solid position in emergent food processing and have seen as serious alternatives to traditional thermal processing. During the last decades, research has been devoted to elucidation of technological and safety issues but also fundamental aspects related with interaction of electric fields (EF) with important macromolecules, such as proteins. Proteins are building blocks for the development of functional networks that can encompass health benefits (i.e. nutritional and bioactive properties) but may be also linked with adverse effects such as neurodegenerative diseases (amyloid fibrils) and immunological responses. The biological function of a protein depends on its tridimensional structure/conformation, and latest research evidences that EF can promote disturbances on protein conformation, change their unfolding mechanisms, aggregation and interaction patterns. This review aims at bringing together these recent findings as well as providing novel perspectives about how EF can shape the behavior of proteins towards the development of innovative foods, aiming at consumers health and wellbeing.This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/ BIO/04469/2019 and UIDB 50006/2020 with funding from FCT/ MCTES through national funds, BioTecNorte operation (NORTE-01- 0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. This work was also supported by the projects AlleRiskAssess â PTDC/BAA-AGR/31720/2017 and NORTE-01-0145-FEDER-031720. Zita Avelar acknowledge the Foundation for Science and Technology (FCT) for its fellowship SFRH/BD/146347/2019info:eu-repo/semantics/publishedVersio